Eisai
Fujirebio, Eisai Partnering on Blood-based Biomarkers for Neurodegenerative Disease
The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.
Eisai Investing up to $15M in Alzheimer's Dx Firm C2N
The investment will support efforts to expand the availability and use of C2N's blood-based biomarker tests for Alzheimer's disease in the US.
Alzheimer's Dx Firms Aim to Take Advantage of Increased Testing Demand Following Leqembi Approval
Premium
Near term, CSF assays and PET imaging will likely remain the methods of choice for evaluating patients for the drug, but blood tests continue to gain traction.
Japanese Consortium Launches Study to Evaluate Utility of Blood-Based Alzheimer's Markers
Shimadzu, Eisai, Oita University, and Usuki City Medical Association are studying the markers in 100 patients using Shimadzu's mass spec technology.
Alzheimer's Drug Discovery Foundation, Pharma Firms Form Biobank Alliance
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.